MAIA Biotechnology, Inc. (NYSEAMERICAN: MAIA) disclosed information relating to its Phase 2 THIO-101 trial in advanced non-small cell lung cancer through a press release on February 4, 2025. According ...

With the Canadian economy experiencing a contraction in November and a recent interest rate cut by the Bank of Canada due to tariff uncertainties, investors are navigating a complex landscape. In such ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

Good news for the sector came January 23 when global pharmaceutical giant AstraZeneca plc announced an eye-popping $820 ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...

IIT Madras launches cancer genome database to transform cancer research in India, aiming to identify biomarkers and ...

In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...

What if microscopic robots could seek out and destroy cancer cells without harming the body? Scientists are developing nanobots that navigate the bloodstream with surgical precision, targeting ...

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) recently disclosed updates to the employment agreements of key executive officers in a Form 8-K filing dated February 1, 2025. The company entered into ...

BeiGene, a global biotech firm that develops cancer medicines, has opened a 400,000-square-foot life sciences facility in ...

In November, virologist Beata Halassy announced to the world that she had cured her own breast cancer using a treatment ...

Former President Joe Biden and his radical leftist allies launched an unprecedented assault on Florida seniors through their ...